0.08Open0.08Pre Close0 Volume38 Open Interest3.00Strike Price0.00Turnover29.74%IV1.32%PremiumDec 20, 2024Expiry Date0.04Intrinsic Value100Multiplier9DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.6299Delta2.6800Gamma38.00Leverage Ratio-0.0033Theta0.0004Rho23.94Eff Leverage0.0018Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet